Capricor Therapeutics Inc
NASDAQ:CAPR

Watchlist Manager
Capricor Therapeutics Inc Logo
Capricor Therapeutics Inc
NASDAQ:CAPR
Watchlist
Price: 18.215 USD -1.49%
Market Cap: 592.7m USD
Have any thoughts about
Capricor Therapeutics Inc?
Write Note

Intrinsic Value

The intrinsic value of one CAPR stock under the Base Case scenario is 21.085 USD. Compared to the current market price of 18.215 USD, Capricor Therapeutics Inc is Undervalued by 14%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CAPR Intrinsic Value
21.085 USD
Undervaluation 14%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Capricor Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for CAPR cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about CAPR?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Capricor Therapeutics Inc

Provide an overview of the primary business activities
of Capricor Therapeutics Inc.

What unique competitive advantages
does Capricor Therapeutics Inc hold over its rivals?

What risks and challenges
does Capricor Therapeutics Inc face in the near future?

Summarize the latest earnings call
of Capricor Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Capricor Therapeutics Inc.

Provide P/S
for Capricor Therapeutics Inc.

Provide P/E
for Capricor Therapeutics Inc.

Provide P/OCF
for Capricor Therapeutics Inc.

Provide P/FCFE
for Capricor Therapeutics Inc.

Provide P/B
for Capricor Therapeutics Inc.

Provide EV/S
for Capricor Therapeutics Inc.

Provide EV/GP
for Capricor Therapeutics Inc.

Provide EV/EBITDA
for Capricor Therapeutics Inc.

Provide EV/EBIT
for Capricor Therapeutics Inc.

Provide EV/OCF
for Capricor Therapeutics Inc.

Provide EV/FCFF
for Capricor Therapeutics Inc.

Provide EV/IC
for Capricor Therapeutics Inc.

Show me price targets
for Capricor Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Capricor Therapeutics Inc?

How accurate were the past Revenue estimates
for Capricor Therapeutics Inc?

What are the Net Income projections
for Capricor Therapeutics Inc?

How accurate were the past Net Income estimates
for Capricor Therapeutics Inc?

What are the EPS projections
for Capricor Therapeutics Inc?

How accurate were the past EPS estimates
for Capricor Therapeutics Inc?

What are the EBIT projections
for Capricor Therapeutics Inc?

How accurate were the past EBIT estimates
for Capricor Therapeutics Inc?

Compare the revenue forecasts
for Capricor Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Capricor Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Capricor Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Capricor Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Capricor Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Capricor Therapeutics Inc with its peers.

Analyze the financial leverage
of Capricor Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Capricor Therapeutics Inc.

Provide ROE
for Capricor Therapeutics Inc.

Provide ROA
for Capricor Therapeutics Inc.

Provide ROIC
for Capricor Therapeutics Inc.

Provide ROCE
for Capricor Therapeutics Inc.

Provide Gross Margin
for Capricor Therapeutics Inc.

Provide Operating Margin
for Capricor Therapeutics Inc.

Provide Net Margin
for Capricor Therapeutics Inc.

Provide FCF Margin
for Capricor Therapeutics Inc.

Show all solvency ratios
for Capricor Therapeutics Inc.

Provide D/E Ratio
for Capricor Therapeutics Inc.

Provide D/A Ratio
for Capricor Therapeutics Inc.

Provide Interest Coverage Ratio
for Capricor Therapeutics Inc.

Provide Altman Z-Score Ratio
for Capricor Therapeutics Inc.

Provide Quick Ratio
for Capricor Therapeutics Inc.

Provide Current Ratio
for Capricor Therapeutics Inc.

Provide Cash Ratio
for Capricor Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Capricor Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Capricor Therapeutics Inc?

What is the current Free Cash Flow
of Capricor Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Capricor Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Capricor Therapeutics Inc

Current Assets 30.7m
Cash & Short-Term Investments 29.5m
Receivables 370k
Other Current Assets 837.2k
Non-Current Assets 7.6m
PP&E 7.3m
Other Non-Current Assets 319.6k
Current Liabilities 22.4m
Accounts Payable 6.2m
Accrued Liabilities 792.7k
Other Current Liabilities 15.4m
Non-Current Liabilities 4.4m
Long-Term Debt 3.4m
Other Non-Current Liabilities 1m
Efficiency

Earnings Waterfall
Capricor Therapeutics Inc

Revenue
27.2m USD
Operating Expenses
-57.2m USD
Operating Income
-30m USD
Other Expenses
2.1m USD
Net Income
-27.9m USD

Free Cash Flow Analysis
Capricor Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Capricor reported significant progress in Q2 2024, particularly with its lead asset, Deramiocel, for Duchenne muscular dystrophy. The company is nearing a Biologics License Application (BLA) submission and targets addressing both skeletal and cardiac symptoms. Recently published data show a 50% delay in disease progression and notable cardiac improvements. The company anticipates up to $700 million from its U.S. partnership with Nippon Shinyaku, aiding commercialization efforts. Financially, the firm saw a net loss of $11 million in Q2. With $29.5 million in cash, operations are funded until Q1 2025. Capricor’s StealthX exosome platform and a promising pipeline bolster its growth strategy.

What is Earnings Call?
Fundamental Scores

CAPR Profitability Score
Profitability Due Diligence

Capricor Therapeutics Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
Declining ROE
26/100
Profitability
Score

Capricor Therapeutics Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

CAPR Solvency Score
Solvency Due Diligence

Capricor Therapeutics Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Long-Term Solvency
Short-Term Solvency
53/100
Solvency
Score

Capricor Therapeutics Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CAPR Price Targets Summary
Capricor Therapeutics Inc

Wall Street analysts forecast CAPR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CAPR is 26.52 USD with a low forecast of 15.15 USD and a high forecast of 42 USD.

Lowest
Price Target
15.15 USD
17% Downside
Average
Price Target
26.52 USD
46% Upside
Highest
Price Target
42 USD
131% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for CAPR?

Click here to dive deeper.

Dividends

Capricor Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for CAPR is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Capricor Therapeutics Inc Logo
Capricor Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

591.4m USD

Dividend Yield

0%

Description

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. The company is headquartered in Beverly Hills, California and currently employs 48 full-time employees. The company went IPO on 2002-06-04. The firm consists of cell therapy program, including CAP-1002 for Duchenne Muscular Dystrophy program and CAP-1002 with CAP-1002 for coronavirus (COVID-19). The Company’s lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is in clinical development for treating Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. Capricor is also developing its exosome technology therapeutic platform. The firm is focused on developing exosomes capable of delivering nucleic acids, including messenger RNA (mRNA) as well as proteins, to treat or prevent a range of diseases. CAP-1002 cell therapy programs initiated Pivotal Phase III, HOPE-3.

Contact

CALIFORNIA
Beverly Hills
8840 Wilshire Blvd Fl 2
+13103583200.0
capricor.com

IPO

2002-06-04

Employees

48

Officers

See Also

Discover More
What is the Intrinsic Value of one CAPR stock?

The intrinsic value of one CAPR stock under the Base Case scenario is 21.085 USD.

Is CAPR stock undervalued or overvalued?

Compared to the current market price of 18.215 USD, Capricor Therapeutics Inc is Undervalued by 14%.

Back to Top